Skip to main content

Autoimmune Hepatitis clinical trials at UC Health
1 in progress, 0 open to eligible people

  • Liver Test Study of Using JKB-122 in AIH Patients

    Sorry, in progress, not accepting new patients

    This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks in subjects with autoimmune hepatitis (AIH) who have liver enzymes that are 1.25 to 10 times the upper limit of normal (ULN) and who have had a failed response to, incomplete response to, intolerant to, ineligible to, or unwilling to take current immunosuppressant therapies. The dose of JKB-122 will be escalated monthly.

    at UC Davis

Last updated: